New hope for women with Tough-to-Treat cervical cancer
NCT ID NCT05838521
Summary
This study is testing an experimental drug called sacituzumab govitecan for women whose cervical cancer has returned or persisted after prior chemotherapy. The drug is designed to deliver chemotherapy directly to cancer cells. Researchers will measure if tumors shrink, how long patients live without the cancer worsening, and the drug's safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Smilow Cancer Hospital at Yale New Haven
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.